Information Provided By:
Fly News Breaks for December 7, 2016
KPTI
Dec 7, 2016 | 06:57 EDT
Wedbush analyst David Nierengarten says that Karyopharm's Selinexor has the "best mix of efficacy, safety and convenience in heavily pretreated (multiple myeloma) patients." The analyst adds that the drug's "unique" mechanism of action "supports combinability" with other drugs, and he predicts that Selinexor will be included within any multiple myeloma treatment that becomes widely used. Nierengarten reiterates a $14 price target and an Outperform rating on Karyopharm.
News For KPTI From the Last 2 Days
There are no results for your query KPTI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.